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Bronchioloalveolar cell carcinoma (BAC) has fascinated physicians with its uniqueepidemiology, pathology, clinical manifestations and natural history when compared with
other non-small cell lung cancer (NSCLC) subtypes. However, the relative rarity of pure BAC
as defined by the WHO, and the inconsistent definitions used in various series, has limited
systematic study of this entity. Retrospective and prospective studies suggest that patients with
BAC treated with cytotoxic chemotherapy have a longer median survival than those with other
subtypes of NSCLC. However, the widely accepted view that BAC is less chemosensitive than
other NSCLCs is not clearly supported by the small body of available literature. Antitumor
activity of cytotoxic agents and the epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors has been documented in phase II trials but no phase III trials have been conducted
in this disease. The observation that profound responses to gefitinib and erlotinib often
occurred in NSCLC patients with BAC, and that EFGR tyrosine kinase domain mutations
were identified in large part by careful study of such patients, serves as a paradigm for
translational research in this disease. The recognition that pure BAC and adenocarcinoma with
BAC features behave similarly and as such represent a relatively common entity will facilitate
accrual to BAC specific studies. Alternatively, stratification of these histologic subtypes in
broader clinical trials in NSCLC is warranted. However, for either strategy to succeed in
advancing our understanding of the molecular biology of BAC, it must be accompanied by
central pathologic review with detailed classification of such and of adequate tissue for
measurement of known or putative targets of action of the agent under study.
The World Health Organization’s (WHO) Classification of thoracic tumors was
revised in 1999, and the BAC tumors were defined to be a subtype of adenocarcinomas
with a pure bronchioloalveolar growth pattern and no evidence of stromal, vascular, or
pleural invasion. Although the revised WHO classification strictly defines BAC as having
absolutely no evidence of invasion, adenocarcinomas can display a range of BAC features
from predominant BAC with only a small focus of invasion, to a lesion that has BAC
features only at the periphery of the tumor. With the recent developments in imaging,
bronchoscopy, and other diagnostic techniques, smaller and more peripherally located
malignant lesions are diagnosed, most of them as adenocarcinomas with or without BAC
features, but also pure BACs. However, many benign or “premalignant” lesions are also
diagnosed and the biological relationship between Atypical Adenomatous Hyperplasia
(AAH), BAC and invasive adenocarcinomas is still to be defined.
In order to gather and discuss the most recent body of scientific literature,
standardize the pathology and imaging criteria and to make a future strategy for clinical
and translational research in this area an international symposium was held in New York,
November 4–6, 2004. The symposium included workshops in the different fields of
expertise, and this current supplement contains the results from these workshops with
subsequent work-up from the different groups of experts.
It is our hope that this supplement will give guidance for future research and
management of patients with BAC or adenocarcinomas with BAC features.
The organizers would like to thank the International Association for the Study of
Lung Cancer (IASLC) and the American Society of Clinical Oncology (ASCO) for their
support to this international conference and for facilitating this international effort to
standardize criteria and define a research strategy in this rapidly evolving field.
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